BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Economic Burden in Adult Patients Diagnosed With Rheumatoid Arthritis (RA) Receiving Treatment With Biologic Disease-modifying Antirheumatic Drugs (bDMARDs)
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 695
- Registration Number
- NCT01136694
Predictors of Adherence to Orencia
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2010-06-03
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 422
- Registration Number
- NCT01136707
Study of Daclatasvir (BMS-790052) Add-on to Standard of Care in Treatment- naïve Patients
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2010-05-18
- Last Posted Date
- 2015-10-23
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 558
- Registration Number
- NCT01125189
- Locations
- 🇺🇸
University Of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Johns Hopkins University, Lutherville, Maryland, United States
🇺🇸Cli, Los Angeles, California, United States
Safety and Pharmacology Study of BMS-866949
- First Posted Date
- 2010-05-17
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 47
- Registration Number
- NCT01124344
- Locations
- 🇸🇪
Local Institution, Uppsala, Sweden
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
- Conditions
- Chronic Lymphocytic LeukemiaFollicular LymphomaAcute Myelogenous LeukemiaDiffuse Large B-Cell Leukemia
- Interventions
- Drug: BMS-936564 (Anti-CXCR4)
- First Posted Date
- 2010-05-11
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 96
- Registration Number
- NCT01120457
- Locations
- 🇺🇸
Ucla-Division Of Hematology/Oncology, Los Angeles, California, United States
🇺🇸The University Of Texas Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸Uc San Diego Moores Cancer Center, La Jolla, California, United States
Safety Study of BMS-823778 in Subjects With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 62
- Registration Number
- NCT01111955
- Locations
- 🇺🇸
Capital Clinical Reserch Center, Olympia, Washington, United States
🇺🇸Farid Marquez, Md, Hialeah, Florida, United States
🇨🇦Local Institution, Quebec, Canada
Safety Study of BMS-823778 in Subjects With Hypercholesterolemia
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 60
- Registration Number
- NCT01112423
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
🇺🇸Sterling Research Grp, Ltd., Cincinnati, Ohio, United States
🇺🇸Osborne Research Center, Little Rock, Arkansas, United States
Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 87
- Registration Number
- NCT01108705
- Locations
- 🇨🇳
Local Institution, Taoyuan, Taiwan
Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-04-16
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 56
- Registration Number
- NCT01105429
- Locations
- 🇺🇸
Profil Institute For Clinical Research, Inc. (Picr), Chula Vista, California, United States
🇺🇸Elite Research Institute, Miami, Florida, United States
🇺🇸Clinical Pharmacology Of Miami Inc., Miami, Florida, United States
PRINCE: Study of Atazanavir (ATV)/Ritonavir (RTV)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2010-04-07
- Last Posted Date
- 2018-05-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 82
- Registration Number
- NCT01099579
- Locations
- 🇹🇭
Local Institution, Bangkok, Thailand